Close Menu

NEW YORK (GenomeWeb) — Agendia today announced a partnership with GeneCast Biotechnology to make its breast cancer tests available in China.

Under the terms of the deal, Beijing-based GeneCast has the exclusive right to market Agendia's MammaPrint and BluePrint tests to Chinese customers. Local physicians will be able to send patient samples to GeneCast's oncology laboratory for testing, the firms said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.